Chugai Pharmaceutical 

$22.26
110
-$0.21-0.93%Friday 20:59

Statistics

Day High
22.55
Day Low
22.19
52W High
34.84
52W Low
18.33
Volume
30,972
Avg. Volume
310,910
Mkt Cap
37.38B
P/E Ratio
28.25
Dividend Yield
2.99%
Dividend
0.67

Upcoming

Dividends

2.99%Dividend Yield
Sep 2026
$0.21
Apr 2026
$0.46
Sep 2025
$0.43
Apr 2025
$0.19
Sep 2024
$0.14
10Y Growth
22.32%
5Y Growth
19.41%
3Y Growth
32.32%
1Y Growth
8.52%

Earnings

Feb 4Expected
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Q3 2026
Next
0.4
0.46
0.53
0.59
Expected EPS
0.4875140264
Actual EPS
N/A

Financials

34.47%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
8.35BRevenue
2.88BNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CHGCY. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap164.67B
Pfizer Inc. competes in various therapeutic areas including oncology, vaccines, and immunology, similar to Chugai's focus areas.
Merck
MRK
Mkt Cap364.26B
Merck & Co., Inc. is a direct competitor in the oncology and immunology sectors, areas where Chugai is actively developing treatments.
Novartis
NVS
Mkt Cap303.12B
Novartis AG operates in the same therapeutic areas as Chugai, including oncology and rheumatology, making it a strong competitor.
Johnson & Johnson
JNJ
Mkt Cap687.89B
Johnson & Johnson, through its pharmaceutical segment Janssen, competes in the oncology, immunology, and neuroscience sectors.
Astrazeneca
AZN
Mkt Cap286.07B
AstraZeneca PLC has a strong presence in oncology, respiratory, and cardiovascular diseases, competing with Chugai's research and drug portfolio.
Bristol-Myers Squibb
BMY
Mkt Cap129.66B
Bristol-Myers Squibb Company competes in the oncology sector, particularly in developing treatments for cancer, a key area for Chugai.
GSK
GSK
Mkt Cap101.13B
GlaxoSmithKline plc competes with Chugai in the areas of oncology and immunology, with a focus on developing innovative medicines and vaccines.
Sanofi
SNY
Mkt Cap116.15B
Sanofi competes across several of the same therapeutic areas as Chugai, including oncology, immunology, and rare diseases.
Takeda Pharmaceutical
TAK
Mkt Cap68.47B
Takeda Pharmaceutical Company Limited, as a major Japanese pharmaceutical, competes directly with Chugai in the domestic market across various therapeutic areas including oncology and gastroenterology.

About

Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company, operating subsidiaries involved in the full lifecycle of drug development, from research and manufacturing to sales, import, and export, serving both Japanese and international markets. Its commercialized product portfolio spans several key therapeutic areas. These include a robust oncology offering with leading treatments like Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda. Additionally, it provides medications for bone health (e.g., Actemra, Edirol, Bonviva), renal conditions (such as Mircera and Oxarol), and neurological or other diverse ailments (including Hemlibra, CellCept, and Enspryng). Beyond its existing offerings, the company maintains an active research and development pipeline. This pipeline features multiple promising candidates targeting oncology, orthopedic and joint disorders, autoimmune diseases, kidney-related conditions, and various neurological or other health issues. Strategic partnerships are central to Chugai's operations, most notably a significant alliance with the Roche Group. The company also fosters collaborative research initiatives with academic institutions. Established in 1925, Chugai's headquarters are located in Tokyo, Japan, and it operates as a key subsidiary of Roche Holding Ltd.
Show More
CEO
Osamu Okuda
Employees
5104
Country
Japan
ISIN
US1712691039
WKN
000A12ABF

Listings

0 Comments

Share your thoughts

FAQs

What is Chugai Pharmaceutical stock price today?▼
The current price of CHGCY is $22.26 USD — it has decreased by -0.93% in the past 24 hours. Watch Chugai Pharmaceutical stock price performance more closely on the chart.
What is Chugai Pharmaceutical stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Chugai Pharmaceutical stocks are traded under the ticker CHGCY.
Is Chugai Pharmaceutical stock price growing?▼
CHGCY stock has fallen by -1.11% compared to the previous week, the month change is a +5% rise, over the last year Chugai Pharmaceutical has showed a -17.16% decrease.
What is Chugai Pharmaceutical market cap?▼
Today Chugai Pharmaceutical has the market capitalization of 37.38B
When is the next Chugai Pharmaceutical earnings date?▼
Chugai Pharmaceutical is going to release the next earnings report on February 4, 2027.
What were Chugai Pharmaceutical earnings last quarter?▼
CHGCY earnings for the last quarter are 0.59 USD per share, whereas the estimation was 0.49 USD resulting in a +21.28% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Chugai Pharmaceutical revenue for the last year?▼
Chugai Pharmaceutical revenue for the last year amounts to 8.35B USD.
What is Chugai Pharmaceutical net income for the last year?▼
CHGCY net income for the last year is 2.88B USD.
Does Chugai Pharmaceutical pay dividends?▼
Yes, CHGCY dividends are paid semi-annual. The last dividend per share was 0.21 . As of today, Dividend Yield (FWD)% is 2.99%.
How many employees does Chugai Pharmaceutical have?▼
As of November 22, 2026, the company has 5,104 employees.
In which sector is Chugai Pharmaceutical located?▼
Chugai Pharmaceutical operates in the Health & Wellness sector.
When did Chugai Pharmaceutical complete a stock split?▼
The last stock split for Chugai Pharmaceutical was on July 6, 2020 with a ratio of 12:1.
Where is Chugai Pharmaceutical headquartered?▼
Chugai Pharmaceutical is headquartered in Tokyo, Japan.